Triggering of Suicidal Erythrocyte Death by Ruxolitinib

Triggering of Suicidal Erythrocyte Death by Ruxolitinib

Background/Aims: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies. Most important side effects include anemia. A common cause of anemia is accelerated suicidal death of erythrocytes or...

Full description

Bibliographic Details
Main Authors: Marilena Briglia, Antonella Fazio, Caterina Faggio, Stefan Laufer, Kousi Alzoubi, Florian Lang
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2015-09-01
Series:Cellular Physiology and Biochemistry
Subjects:
Phosphatidylserine
Cell volume
Eryptosis
Oxidative stress
Calcium
Online Access:http://www.karger.com/Article/FullText/430394

Internet

http://www.karger.com/Article/FullText/430394

Similar Items